June 24, 2022

The U.S. FDA has approved two new indications for Breyanzi® (lisocabtagene maraleucel), in the treatment of large B-cell lymphoma (LBCL).

  • Breyanzi is now approved to treat LBCL in adults who:
    • Have disease refractory to first-line chemoimmunotherapy or that has relapsed within 12 months of first-line chemoimmunotherapy; or
    • Are not eligible for hematopoietic stem cell transplant due to comorbidities or age and have disease refractory to first-line chemoimmunotherapy or that has relapsed after firstline chemoimmunotherapy.
  • First FDA approved in 2021, Breyanzi is also indicated to treat relapsed or refractory LBCL in adults who have received two or more lines of systemic therapy.
  • Recommended dosing is individualized, as Breyanzi is a CAR-T therapy made using the patient’s own immune cells.

 

 

July 31, 2022

Brand Medications with Generic Alternatives Anticipated to be Approved in August

Read More
July 19, 2022

FDA Approves First Therapy for Repigmentation in Vitiligo

Read More
July 15, 2022

Zonisade Approved to Treat Seizures

Read More
July 14, 2022

Xalkori Granted New Indication to Treat Non-Cancerous Tumors

Read More